104 results on '"Bonenfant, Debora"'
Search Results
2. Protein Tyrosine Phosphatase SHP2 Controls Interleukin-8 Expression in Breast Cancer Cells
3. BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma
4. BET bromodomain inhibitors regulate keratinocyte plasticity
5. Quantitation of Changes in Protein Phosphorylation: A Simple Method Based on Stable Isotope Labeling and Mass Spectrometry
6. CLK2 inhibition ameliorates autistic features associated with SHANK3 deficiency
7. Abstract 3449: Development of MRT-2359, an orally bioavailable GSPT1 molecular glue degrader, for the treatment of lung cancers with MYC-induced translational addiction
8. Supplementary Table 1 from Mammary Tumor Formation and Metastasis Evoked by a HER2 Splice Variant
9. Supplementary Table 2 from Mammary Tumor Formation and Metastasis Evoked by a HER2 Splice Variant
10. Data from Targeting Fibroblast Growth Factor Receptors Blocks PI3K/AKT Signaling, Induces Apoptosis, and Impairs Mammary Tumor Outgrowth and Metastasis
11. Supplementary Figure 3 from Targeting Fibroblast Growth Factor Receptors Blocks PI3K/AKT Signaling, Induces Apoptosis, and Impairs Mammary Tumor Outgrowth and Metastasis
12. Supplementary Table 7 from Targeting Fibroblast Growth Factor Receptors Blocks PI3K/AKT Signaling, Induces Apoptosis, and Impairs Mammary Tumor Outgrowth and Metastasis
13. Supplementary Figure 1 from Targeting Fibroblast Growth Factor Receptors Blocks PI3K/AKT Signaling, Induces Apoptosis, and Impairs Mammary Tumor Outgrowth and Metastasis
14. Supplementary Table 2 from Targeting Fibroblast Growth Factor Receptors Blocks PI3K/AKT Signaling, Induces Apoptosis, and Impairs Mammary Tumor Outgrowth and Metastasis
15. Supplementary Figures from Mammary Tumor Formation and Metastasis Evoked by a HER2 Splice Variant
16. Supplementary Figure 4 from Targeting Fibroblast Growth Factor Receptors Blocks PI3K/AKT Signaling, Induces Apoptosis, and Impairs Mammary Tumor Outgrowth and Metastasis
17. Supplementary Figure 6 from Targeting Fibroblast Growth Factor Receptors Blocks PI3K/AKT Signaling, Induces Apoptosis, and Impairs Mammary Tumor Outgrowth and Metastasis
18. Supplementary Figure 2 from Targeting Fibroblast Growth Factor Receptors Blocks PI3K/AKT Signaling, Induces Apoptosis, and Impairs Mammary Tumor Outgrowth and Metastasis
19. Supplementary Table 1 from Targeting Fibroblast Growth Factor Receptors Blocks PI3K/AKT Signaling, Induces Apoptosis, and Impairs Mammary Tumor Outgrowth and Metastasis
20. Data from Mammary Tumor Formation and Metastasis Evoked by a HER2 Splice Variant
21. Supplementary Methods and Materials from Targeting Fibroblast Growth Factor Receptors Blocks PI3K/AKT Signaling, Induces Apoptosis, and Impairs Mammary Tumor Outgrowth and Metastasis
22. Supplementary Figure Legends 1-6,Table Legends 1-7 from Targeting Fibroblast Growth Factor Receptors Blocks PI3K/AKT Signaling, Induces Apoptosis, and Impairs Mammary Tumor Outgrowth and Metastasis
23. Supplementary Table 5 from Targeting Fibroblast Growth Factor Receptors Blocks PI3K/AKT Signaling, Induces Apoptosis, and Impairs Mammary Tumor Outgrowth and Metastasis
24. Supplementary Table 6 from Targeting Fibroblast Growth Factor Receptors Blocks PI3K/AKT Signaling, Induces Apoptosis, and Impairs Mammary Tumor Outgrowth and Metastasis
25. Supplementary Figure 5 from Targeting Fibroblast Growth Factor Receptors Blocks PI3K/AKT Signaling, Induces Apoptosis, and Impairs Mammary Tumor Outgrowth and Metastasis
26. Supplementary Table 4 from Targeting Fibroblast Growth Factor Receptors Blocks PI3K/AKT Signaling, Induces Apoptosis, and Impairs Mammary Tumor Outgrowth and Metastasis
27. Supplementary Table 3B from Targeting Fibroblast Growth Factor Receptors Blocks PI3K/AKT Signaling, Induces Apoptosis, and Impairs Mammary Tumor Outgrowth and Metastasis
28. A novel HERC4-dependent glue degrader targeting STING
29. Biophotonics Applied to Proteomics
30. TMEM41B is a novel regulator of autophagy and lipid mobilization
31. Inhibition of DDR1‐BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer
32. Mass Spectrometric Analysis of Protein Phosphorylation
33. Abstract 3929: Identification of MRT-2359 a potent, selective and orally bioavailable GSPT1-directed molecular glue degrader (MGD) for the treatment of cancers with Myc-induced translational addiction
34. NEURODEVELOPMENT: CLK2 inhibition ameliorates autistic features associated with SHANK3 deficiency
35. Tu1727 MRT-6160, A VAV1-DIRECTED MOLECULAR GLUE DEGRADER, INHIBITS DISEASE PROGRESSION IN A T-CELL TRANSFER MEDIATED MURINE COLITIS MODEL CONCOMITANT WITH REDUCED CALPROTECTIN EXPRESSION
36. Abstract LBA004: Identification of GSPT1-directed molecular glue degrader (MGD) for the treatment of Myc-driven breast cancer
37. Analysis of Dynamic Changes in Post-translational Modifications of Human Histones during Cell Cycle by Mass Spectrometry
38. Characterization of Histone H2A and H2B Variants and Their Post-translational Modifications by Mass Spectrometry
39. Therapeutic Assessment of Targeting ASNS Combined with l-Asparaginase Treatment in Solid Tumors and Investigation of Resistance Mechanisms
40. Therapeutic assessment of targeting ASNS combined with L-Asparaginase treatment in solid tumors and investigation of resistance mechanisms
41. Genome-wide CRISPR screening reveals genetic modifiers of mutant EGFR dependence in human NSCLC
42. Author response: Genome-wide CRISPR screening reveals genetic modifiers of mutant EGFR dependence in human NSCLC
43. Two TOR Complexes, Only One of which Is Rapamycin Sensitive, Have Distinct Roles in Cell Growth Control
44. TMEM 41B is a novel regulator of autophagy and lipid mobilization
45. Inhibition of DDR 1‐ BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer
46. Additional file 7: of Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition
47. Additional file 4: of Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition
48. Genome-wide CRISPR screening reveals genetic modifiers of mutant EGFR dependence in human NSCLC.
49. Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition
50. ANO1/TMEM16A interacts with EGFR and correlates with sensitivity to EGFR-targeting therapy in head and neck cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.